Loading clinical trials...
Loading clinical trials...
Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients
The purpose of this study is to evaluate the sensitivity and specificity of "A-PROTEIN" levels in patients with brain tumors. A-PROTEIN levels will be analyzed both pre and post treatment. Levels in blood and/or cerebrospinal fluid (CSF) will be analyzed and correlated with the underlying diagnosis and outcome.
* Patients will be identified at the time of presentation to their neurologist, neurosurgeon or oncologist. * Blood or cerebrospinal fluid will be collected for this study only when they are being collected for other reasons before and after each surgery. Samples will also be collected after any event such as significant change in symptoms or radiographic progression. * Once the patients condition has been stabilized, samples will be take at regular intervals of \>= 1 month. The duration of this study is 24 months.
Age
0 - 77 years
Sex
ALL
Healthy Volunteers
No
Dana Farber Cancer Institite
Boston, Massachusetts, United States
Start Date
June 1, 1998
Primary Completion Date
February 1, 2004
Completion Date
August 1, 2009
Last Updated
November 23, 2016
54
ACTUAL participants
A PROTEIN level
OTHER
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions